Akero Therapeutics, Inc. (AKRO)
NASDAQ: AKRO · Real-Time Price · USD
39.98
-2.74 (-6.41%)
Mar 31, 2025, 10:53 AM EDT - Market open
Akero Therapeutics Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for Akero Therapeutics stock have an average target of 76.29, with a low estimate of 38 and a high estimate of 109. The average target predicts an increase of 90.82% from the current stock price of 39.98.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Akero Therapeutics stock from 9 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
---|---|---|---|---|---|---|
Strong Buy | 3 | 4 | 4 | 5 | 5 | 5 |
Buy | 5 | 3 | 3 | 4 | 4 | 4 |
Hold | 1 | 1 | 1 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 9 | 8 | 8 | 9 | 9 | 9 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $72 → $75 | Strong Buy | Maintains | $72 → $75 | +87.59% | Mar 3, 2025 |
UBS | UBS | Strong Buy Maintains $42 → $109 | Strong Buy | Maintains | $42 → $109 | +172.64% | Jan 31, 2025 |
B of A Securities | B of A Securities | Hold → Strong Buy Upgrades $35 → $63 | Hold → Strong Buy | Upgrades | $35 → $63 | +57.58% | Jan 30, 2025 |
Morgan Stanley | Morgan Stanley | Buy Maintains $46 → $96 | Buy | Maintains | $46 → $96 | +140.12% | Jan 28, 2025 |
Citigroup | Citigroup | Strong Buy Maintains $65 → $80 | Strong Buy | Maintains | $65 → $80 | +100.10% | Jan 28, 2025 |
Financial Forecast
Revenue This Year
n/a
from 345.98M
Revenue Next Year
n/a
EPS This Year
-4.77
from -3.75
EPS Next Year
-4.98
from -4.77
Revenue Forecast
Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | n/a | 30.5M | 121.9M | ||
Avg | n/a | 4.2M | 29.6M | ||
Low | n/a | n/a | n/a |
Revenue Growth
Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | - | - | 2,783.3% | ||
Avg | - | - | 600.3% | ||
Low | - | - | - |
EPS Forecast
EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | -4.06 | -4.11 | -1.23 | ||
Avg | -4.77 | -4.98 | -1.19 | ||
Low | -6.12 | -6.44 | -1.15 |
EPS Growth
EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | - | - | - | ||
Avg | - | - | - | ||
Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.